市場調查報告書
商品編碼
1382482
睡眠藥物市場規模 - 按類型(處方藥、非處方藥)、藥物類別(苯二氮平類藥物、抗憂鬱藥、抗組織胺)、睡眠障礙類型、2023-2032 年全球預測Sleep Medications Market Size - By Type (Prescription-based, OTC), Drug Class (Benzodiazepines, Antidepressants, Antihistamines), Sleep Disorder Type, Global Forecast 2023-2032 |
預計從 2023 年到 2032 年,睡眠藥物市場規模將以超過 6.8% 的CAGR成長。不斷上升的壓力水平和忙碌的生活方式導致全球睡眠障礙患病率激增。老年人口的不斷成長、慢性病發病率的增加以及人們對睡眠習慣重要性的認知不斷提高,都推動了產品需求。
此外,久坐的生活方式和精神健康疾病的高盛行率進一步加速了有效睡眠藥物的採用,促進了市場擴張。哈佛醫學院和昆士蘭大學研究人員共同領導的一項大規模研究表明,全球 50% 的人口到 75 歲時將患上至少一種精神健康疾病。隨著心理健康問題的發展,未來幾年對睡眠藥物的需求也會增加。
整個睡眠藥物市場根據類型、藥物類別、睡眠障礙類型和地區進行分類。
預計 2023 年至 2032 年,非處方藥領域的CAGR將達到 7.1%,這主要是由於易於取得以及消費者對自我藥療的日益偏好。隨著幾種可快速緩解常見睡眠障礙的非處方藥睡眠輔助劑的推出,消費者越來越傾向於使用這些藥物。在領先製藥公司採用的產品創新和行銷策略的支持下,對非處方安眠藥的需求持續成長。
預計 2023 年至 2032 年,不寧腿睡眠障礙 (RLSD) 領域的CAGR將達到近8.4%。普通人群對這種疾病的認知不斷提高,導致對針對這種特殊病症的特定藥物的需求增加。市場參與者積極參與研發活動,以推出有效的配方。確診病例數量的增加以及專注於解決其症狀的新型治療方案的開發將有助於該細分市場的成長。
由於中國、印度和日本等國家的快速城市化、生活方式的改變以及睡眠障礙盛行率的增加,2023年至2032年亞太地區睡眠藥物市場的CAGR將達到7.9%左右。該地區的醫療基礎設施正在不斷改善,加上人們對睡眠健康重要性的認知不斷提高,預計將推動市場成長。這些製藥公司策略性地致力於透過推出客製化產品和加強分銷網路來擴大其在亞太市場的影響力,從而充分利用該地區不斷成長的機會。
Sleep medications market size is predicted to grow at over 6.8% CAGR from 2023 to 2032. The rising stress levels and hectic lifestyles have led to an upsurge in the prevalence of sleep disorders globally. The growing elderly population, increasing incidences of chronic diseases, along with the improved awareness about the importance of sleep routine are fueling the product demand.
Moreover, the adoption of sedentary lifestyles and the high prevalence of mental health disorders have further accelerated the adoption of effective sleep medications, fostering market expansion. According to a large-scale study co-led by researchers at Harvard Medical School and University of Queensland, 50% of the global population will develop at least one mental health disorder by the age of 75 years. As mental health issues develop, the need for sleep medications will also increase in the coming years.
The overall sleep medications market is classified based on type, drug class, sleep disorder type, and region.
The OTC drug segment is expected to observe 7.1% CAGR from 2023 to 2032, primarily due to the ease of accessibility and the growing preference for self-medication among the consumers. With the introduction of several OTC sleep aids that offer quick relief from common sleep disorders, consumers are increasingly inclined towards these medications. The demand for OTC sleep drugs continue to boost, supported by the product innovations and marketing strategies adopted by leading pharmaceutical companies.
The restless legs sleep disorder (RLSD) segment is anticipated to witness nearly 8.4% CAGR during 2023 and 2032. The rising awareness about the ailment among the common population is leading to an increased demand for specific medications catering to this particular condition. The market players are actively engaged in R&D activities to introduce effective formulations. The increasing number of diagnosed cases and the development of novel treatment options focusing on addressing its symptoms will aid the segment growth.
Asia Pacific sleep medication market will observe around 7.9% CAGR from 2023 to 2032 owing to the rapid urbanization, changing lifestyle patterns, and the increasing prevalence of sleep disorders in countries such as China, India, and Japan. The region is witnessing improvement in healthcare infrastructure, which along with the rising awareness about the importance of sleep health is expected to drive the market growth. The pharma companies are strategically focusing on expanding their presence in the Asia Pacific market by launching tailored products and strengthening distribution networks, thereby capitalizing on the growing opportunities in this region.